Equities Analysts Offer Predictions for AUPH FY2025 Earnings

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) – Investment analysts at HC Wainwright increased their FY2025 earnings per share (EPS) estimates for Aurinia Pharmaceuticals in a report issued on Wednesday, November 5th. HC Wainwright analyst A. He now forecasts that the biotechnology company will post earnings per share of $0.74 for the year, up from their prior forecast of $0.65. HC Wainwright has a “Buy” rating and a $17.00 price target on the stock. The consensus estimate for Aurinia Pharmaceuticals’ current full-year earnings is $0.11 per share. HC Wainwright also issued estimates for Aurinia Pharmaceuticals’ Q4 2025 earnings at $0.19 EPS, Q1 2026 earnings at $0.18 EPS, Q3 2026 earnings at $0.15 EPS and FY2026 earnings at $0.64 EPS.

A number of other research firms also recently weighed in on AUPH. Royal Bank Of Canada reiterated a “sector perform” rating and set a $15.00 price target (up previously from $9.00) on shares of Aurinia Pharmaceuticals in a research note on Wednesday. Jefferies Financial Group upgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their target price for the company from $10.00 to $21.00 in a research report on Friday. Bloom Burton cut shares of Aurinia Pharmaceuticals from a “moderate buy” rating to a “hold” rating in a research note on Wednesday. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $17.67.

Aurinia Pharmaceuticals Stock Performance

AUPH opened at $14.61 on Friday. The stock’s 50 day simple moving average is $12.28 and its 200-day simple moving average is $10.17. The company has a current ratio of 5.23, a quick ratio of 4.63 and a debt-to-equity ratio of 0.18. The stock has a market cap of $1.92 billion, a PE ratio of 33.98 and a beta of 1.30. Aurinia Pharmaceuticals has a 1 year low of $6.55 and a 1 year high of $16.20.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.23 EPS for the quarter, beating the consensus estimate of $0.16 by $0.07. Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%.The firm had revenue of $73.47 million during the quarter, compared to analysts’ expectations of $67.70 million. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the company. Nuveen LLC acquired a new position in Aurinia Pharmaceuticals in the first quarter valued at about $10,014,000. Qube Research & Technologies Ltd raised its stake in shares of Aurinia Pharmaceuticals by 45.1% in the second quarter. Qube Research & Technologies Ltd now owns 1,242,512 shares of the biotechnology company’s stock valued at $10,524,000 after acquiring an additional 386,364 shares during the last quarter. Jupiter Asset Management Ltd. boosted its holdings in shares of Aurinia Pharmaceuticals by 24.1% in the 2nd quarter. Jupiter Asset Management Ltd. now owns 933,862 shares of the biotechnology company’s stock worth $7,910,000 after acquiring an additional 181,093 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Aurinia Pharmaceuticals by 34.1% in the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 746,229 shares of the biotechnology company’s stock worth $6,000,000 after acquiring an additional 189,775 shares in the last quarter. Finally, Trexquant Investment LP grew its position in Aurinia Pharmaceuticals by 58.5% during the 1st quarter. Trexquant Investment LP now owns 700,638 shares of the biotechnology company’s stock worth $5,633,000 after acquiring an additional 258,620 shares during the last quarter. Institutional investors and hedge funds own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.